BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 38457424)

  • 1. Five-year clinical outcomes of scanning carbon-ion radiotherapy for prostate cancer.
    Takakusagi Y; Koge H; Kano K; Shima S; Tsuchida K; Mizoguchi N; Yoshida D; Kamada T; Katoh H
    PLoS One; 2024; 19(3):e0290617. PubMed ID: 38457424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preliminary result of carbon-ion radiotherapy using the spot scanning method for prostate cancer.
    Takakusagi Y; Katoh H; Kano K; Anno W; Tsuchida K; Mizoguchi N; Serizawa I; Yoshida D; Kamada T
    Radiat Oncol; 2020 May; 15(1):127. PubMed ID: 32460889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term clinical outcomes after 12-fractionated carbon-ion radiotherapy for localized prostate cancer.
    Sato H; Kasuya G; Ishikawa H; Nomoto A; Ono T; Nakajima M; Isozaki Y; Yamamoto N; Iwai Y; Nemoto K; Ichikawa T; Tsuji H;
    Cancer Sci; 2021 Sep; 112(9):3598-3606. PubMed ID: 34107139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment outcome of high-dose image-guided intensity-modulated radiotherapy using intra-prostate fiducial markers for localized prostate cancer at a single institute in Japan.
    Takeda K; Takai Y; Narazaki K; Mitsuya M; Umezawa R; Kadoya N; Fujita Y; Sugawara T; Kubozono M; Shimizu E; Abe K; Shirata Y; Ishikawa Y; Yamamoto T; Kozumi M; Dobashi S; Matsushita H; Chida K; Ishidoya S; Arai Y; Jingu K; Yamada S
    Radiat Oncol; 2012 Jul; 7():105. PubMed ID: 22770471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An external validation of the Candiolo nomogram in a cohort of prostate cancer patients treated by external-beam radiotherapy.
    Gabriele D; Guarneri A; Bartoncini S; Munoz F; Tamponi M; Russo F; Stamatakos G; Guiot C; Regge D; Ricardi U
    Radiat Oncol; 2021 May; 16(1):85. PubMed ID: 33952288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ten-Year Outcomes of Moderately Hypofractionated (70 Gy in 28 fractions) Intensity Modulated Radiation Therapy for Localized Prostate Cancer.
    Abu-Gheida I; Reddy CA; Kotecha R; Weller MA; Shah C; Kupelian PA; Mian O; Ciezki JP; Stephans KL; Tendulkar RD
    Int J Radiat Oncol Biol Phys; 2019 Jun; 104(2):325-333. PubMed ID: 30721720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Outcomes of Scanning Carbon-ion Radiotherapy for Soft Tissue Sarcoma of the Extremities.
    Takakusagi Y; Serizawa I; Koge H; Kano K; Shima S; Tsuchida K; Mizoguchi N; Yoshida D; Katoh H; Hiruma T; Kamada T
    Anticancer Res; 2022 Jul; 42(7):3701-3706. PubMed ID: 35790269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial.
    Aluwini S; Pos F; Schimmel E; Krol S; van der Toorn PP; de Jager H; Alemayehu WG; Heemsbergen W; Heijmen B; Incrocci L
    Lancet Oncol; 2016 Apr; 17(4):464-474. PubMed ID: 26968359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome and toxicity for patients treated with intensity modulated radiation therapy for localized prostate cancer.
    Vora SA; Wong WW; Schild SE; Ezzell GA; Andrews PE; Ferrigni RG; Swanson SK
    J Urol; 2013 Aug; 190(2):521-6. PubMed ID: 23415964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Moderate Hypofractionation with Simultaneous Integrated Boost in Prostate Cancer: Long-term Results of a Phase I-II Study.
    Di Muzio NG; Fodor A; Noris Chiorda B; Broggi S; Mangili P; Valdagni R; Dell'Oca I; Pasetti M; Deantoni CL; Chiara A; Berardi G; Briganti A; Calandrino R; Cozzarini C; Fiorino C
    Clin Oncol (R Coll Radiol); 2016 Aug; 28(8):490-500. PubMed ID: 26961088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significant impact of biochemical recurrence on overall mortality in patients with high-risk prostate cancer after carbon-ion radiotherapy combined with androgen deprivation therapy.
    Kasuya G; Ishikawa H; Tsuji H; Nomiya T; Makishima H; Kamada T; Akakura K; Suzuki H; Shimazaki J; Haruyama Y; Kobashi G; Tsujii H;
    Cancer; 2016 Oct; 122(20):3225-3231. PubMed ID: 27351298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Standard vs Dose-Escalated Radiation Therapy for Patients With Intermediate-Risk Prostate Cancer: The NRG Oncology RTOG 0126 Randomized Clinical Trial.
    Michalski JM; Moughan J; Purdy J; Bosch W; Bruner DW; Bahary JP; Lau H; Duclos M; Parliament M; Morton G; Hamstra D; Seider M; Lock MI; Patel M; Gay H; Vigneault E; Winter K; Sandler H
    JAMA Oncol; 2018 Jun; 4(6):e180039. PubMed ID: 29543933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term outcome of a moderately hypofractionated, intensity-modulated radiotherapy approach using an endorectal balloon for patients with localized prostate cancer.
    Teh BS; Lewis GD; Mai W; Pino R; Ishiyama H; Butler EB
    Cancer Commun (Lond); 2018 Apr; 38(1):11. PubMed ID: 29764515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Image-guided dose-escalated radiation therapy for localized prostate cancer with helical tomotherapy.
    Barelkowski T; Wust P; Kaul D; Zschaeck S; Wlodarczyk W; Budach V; Ghadjar P; Beck M
    Strahlenther Onkol; 2020 Mar; 196(3):229-242. PubMed ID: 31873779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intensity-modulated radiation therapy from 70Gy to 80Gy in prostate cancer: six- year outcomes and predictors of late toxicity.
    Jolnerovski M; Salleron J; Beckendorf V; Peiffert D; Baumann AS; Bernier V; Huger S; Marchesi V; Chira C
    Radiat Oncol; 2017 Jun; 12(1):99. PubMed ID: 28622770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Moderately Hypofractionated Helical Tomotherapy for Prostate Cancer: Ten-year Experience of a Mono-institutional Series of 415 Patients.
    Cozzi S; Ruggieri MP; Alì E; Ghersi SF; Vigo F; Augugliaro M; Giaccherini L; Iori F; Najafi M; Bardoscia L; Botti A; Trojani V; Ciammella P; Iotti C
    In Vivo; 2023; 37(2):777-785. PubMed ID: 36881094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypofractionated Intensity-modulated Radiotherapy for Intermediate- and High-risk Prostate Cancer: A Retrospective Study.
    Kubo N; Kawamura H; Oike T; Sato H; Iwanaga M; Mizukami T; Adachi A; Matsui H; Ito K; Suzuki K; Nakano T
    In Vivo; 2019; 33(4):1235-1241. PubMed ID: 31280214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A dose escalated fiducial marker-based image guided radical radiotherapy in locally advanced prostate cancers: A single institute experience from India.
    Gupta PK; Rastogi N; Maria Das KJ; Kumar S
    J Cancer Res Ther; 2023; 19(2):382-388. PubMed ID: 37006073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of Carbon-ion Radiotherapy for Prostate Cancer After Rectal Cancer Surgery.
    Takakusagi Y; Koge H; Kano K; Shima S; Tsuchida K; Mizoguchi N; Yoshida D; Kamada T; Katoh H
    Anticancer Res; 2023 Jun; 43(6):2691-2695. PubMed ID: 37247892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Safety for Scanning Carbon-Ion Radiotherapy in Hemodialysis Patients With Prostate Cancer.
    Takakusagi Y; Suga M; Kusano Y; Kano K; Shima S; Tsuchida K; Mizoguchi N; Serizawa I; Yoshida D; Kamada T; Minohara S; Katoh H
    Cureus; 2022 Feb; 14(2):e22214. PubMed ID: 35308759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.